ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.999,62
0,36%
S&P 500
5.420,13
-0,25%
US Dollar vs BRL
5,354
-0,17%
Bitcoin
66.834,85
0,12%
Brent Oil
82,235
0,32%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) Notícias

BIIB

Biogen (BIIB)

Biogen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIIB
DataHoraFonteTítuloCódigoCompanhia
10/06/202406:45PR Newswire (US)Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmNASDAQ:BIIBBiogen Inc
09/06/202420:37GlobeNewswire Inc.FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
09/06/202420:30PR Newswire (US)FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseNASDAQ:BIIBBiogen Inc
05/06/202406:45PR Newswire (US)Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIBNASDAQ:BIIBBiogen Inc
04/06/202410:10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNASDAQ:BIIBBiogen Inc
03/06/202408:30GlobeNewswire Inc.Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air TravelNASDAQ:BIIBBiogen Inc
30/05/202417:51GlobeNewswire Inc.Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALSNASDAQ:BIIBBiogen Inc
23/05/202408:40IH Market NewsOpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More NewsNASDAQ:BIIBBiogen Inc
22/05/202408:30GlobeNewswire Inc.Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology BiosciencesNASDAQ:BIIBBiogen Inc
16/05/202408:30GlobeNewswire Inc.Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
16/05/202408:30PR Newswire (US)Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
14/05/202420:33GlobeNewswire Inc.Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
14/05/202420:30PR Newswire (US)Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
02/05/202408:30GlobeNewswire Inc.Biogen Reports Progress on Corporate Responsibility PrioritiesNASDAQ:BIIBBiogen Inc
31/03/202420:30PR Newswire (US)Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDANASDAQ:BIIBBiogen Inc
06/03/202409:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:BIIBBiogen Inc
04/03/202418:15GlobeNewswire Inc.Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingNASDAQ:BIIBBiogen Inc
26/02/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
23/02/202409:00GlobeNewswire Inc.Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPNASDAQ:BIIBBiogen Inc
22/02/202412:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
13/02/202409:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
12/02/202421:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
12/02/202418:06GlobeNewswire Inc.Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaNASDAQ:BIIBBiogen Inc
09/01/202419:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
19/12/202309:30GlobeNewswire Inc.Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionNASDAQ:BIIBBiogen Inc
15/12/202311:05GlobeNewswire Inc.CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative DiseaseNASDAQ:BIIBBiogen Inc
14/12/202308:30GlobeNewswire Inc.ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:BIIBBiogen Inc
08/11/202318:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
08/11/202310:19IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:BIIBBiogen Inc
06/11/202319:44KR Market News월스트리트 상승, 시장은 연준 연사 및 재무부 경매 주목NASDAQ:BIIBBiogen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIIB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AMAR3
LOJAS MARISA ON
BOV
TELB4
TELEBRAS PN
BOV
OIBR3
OI ON
BOV
COGN3
COGNA ON
BOV
AMER3
Americanas ON
BOV
HAGA3
HAGA ON
BOV
TECN3
TECHNOS ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
JHSF3
JHSF PART ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
RCSL3
RECRUSUL ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados